Smartomics

Axia Medicine

Smartomics

The Amazon of Precision Medicine

Cambridge, UK

GBR

For-profit, including B-Corp or similar models

Life-saving health data is lost, fragmented, or inaccessible, delaying treatment, reducing diagnostic accuracy, and limiting access to precision medicine. This disproportionately impacts syndromic patients, underserved communities, and those who cannot afford costly genetic or diagnostic tests. Without access to their own data, millions are excluded from research, clinical trials, and personalized treatments. The scale is massive: 50% of the world’s population will face a chronic disease, yet their data remains locked in silos. In the U.S., 80% of healthcare data is unstructured, and 97% goes unused in research. This leads to 30% of redundant tests and $200B in waste annually. Low-income and minority populations suffer the most, often excluded from precision medicine due to cost barriers—many cannot afford a $500 genetic test to access life-saving insights. Axia Medicine addresses this by giving all individuals, regardless of income, control over all their health data—genomics, clinical records, and real-world evidence. Our platform enables direct access to D2C health services and biopharma studies, ensuring that data inclusion translates to health equity. By transforming passive data into an actionable asset, we drive better outcomes, faster innovation, and a future where precision medicine is accessible to all.

Axia Medicine is a patient-driven platform that unlocks full control over health data, enabling individuals to access, use, and benefit from their own clinical and genomic information. Instead of data being locked in hospitals, labs, and research institutions, Axia aggregates, structures, and makes it usable—at no cost to the patient. How does it work? Patients upload or link their clinical records, genetic data, and real-world health insights into a secure personal data vault. Our system standardizes, validates, and enriches this data, making it usable for D2C health services, clinical trials, and research collaborations. Patients receive direct offers from biopharma and health services, ensuring equitable access to cutting-edge care and financial benefits—without needing to pay for expensive tests upfront. Our platform is built on secure, privacy-first architecture with AI-powered data structuring and multimodal integration, ensuring data remains under patient control. Unlike traditional data marketplaces, Axia keeps data private—researchers only get access if patients approve. This solution ensures that precision medicine, clinical trials, and emerging therapies are available to all communities, regardless of income or background.

Axia Medicine serves syndromic patients, underserved communities, and individuals excluded from precision medicine due to cost or data inaccessibility. These include people with chronic, rare, or complex conditions, as well as those unable to afford expensive diagnostic tests that could guide life-saving treatment. Today, these patients face delayed diagnoses, ineffective treatments, and exclusion from clinical trials because their health data is scattered, incomplete, or controlled by institutions, not them. Low-income and minority populations are disproportionately affected—many cannot afford a $500 genetic test or access specialized care. Axia removes these barriers by giving patients direct access to all their health data—including clinical records, genomics, and real-world insights—at no cost. Through our platform, they can find precision health services, match with biopharma trials, and get financial benefits for contributing to research. This ensures that cutting-edge treatments and innovations are not just for those who can pay but for everyone, regardless of income or background. By shifting control of health data to patients, we improve early diagnosis, expand access to personalized medicine, and accelerate innovation—making health equity a reality, not an afterthought.